Skyrizi 600 mg concentrate for solution for infusion

DRUG2 trials

Sponsors

Universitair Medisch Centrum Groningen

Conditions

Inflammatory Bowel Disease (IBD)

Phase 1

Investigating the safety, feasibility, and optimal dose of risankizumab-800CW for visualizing drug targeting in Inflammatory Bowel Disease

RecruitingCTIS2024-515358-25-00

Universitair Medisch Centrum GroningenInflammatory Bowel Disease (IBD)

Start: 2024-11-08Target: 18Updated: 2024-09-05

Dual wavelength fluorescence imaging using fluorescently labelled adalimumab and risankizumab for visualizing drug targeting in Inflammatory Bowel Diseases (VOYAGER)

Not yet recruitingCTIS2025-521420-30-00

Universitair Medisch Centrum GroningenInflammatory Bowel Disease (IBD)

Target: 30Updated: 2026-01-06